Chimeric antibody against drug-resistant cancers and process...

Details Chimeric antibody against drug-resistant cancers and process... Chimeric antibody against drug-resistant cancers and process...

C - Chemistry, Metallurgy

12

N

530/15.04, 195/1

C12N 15/62 (2006.01) A61K 39/395 (2006.01) C07K 16/30 (2006.01) C07K 16/46 (2006.01) C12N 5/10 (2006.01) C12N 5/18 (2006.01) C12N 15/02 (2006.01) C12N 15/06 (2006.01) C12N 15/13 (2006.01) C12P 21/00 (2006.01) C12P 21/08 (2006.01) G01N 33/574 (2006.01) G01N 33/577 (2006.01)

Patent

CA 2025695

Abstract A monoclonal antibody, MRK16, reactive to the multidrug transporter P-glycoprotein, has been generated in an effort to devise an effective treatment for human drug-resistant cancers. The monoclonal antibody inhibited the growth of human drug-resistant tumor cells in a xenograft model, suggesting its potential usefulness in the immunotherapy of drug-resistant cancers. A recombinant chimeric antibody has been developed by joining the antigen-recognizing variable regions of MRK16 to the constant regions of human antibodies. When human effector cells were used, the chimeric antibody MH162 was more effective in killing drug-resistant tumor cells than the all-mouse monoclonal MRK16. The chimeric antibody against the multidrug transporter P-glycoprotein will be a useful agent in immunotherapy of human drug-resistant cancers.

Affiliated with

Also associated with

Rating

Chimeric antibody against drug-resistant cancers and process... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chimeric antibody against drug-resistant cancers and process..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric antibody against drug-resistant cancers and process... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1773063